Table 6 Survival and recurrence data of the study patients (TACE Transarterial chemoembolization, RFA Radiofrequency ablation, MWA Microwave ablation)
Variables | All (N = 315) | Group I (N = 88) | Group II (N = 167) | Group III (N = 60) | P value |
|---|---|---|---|---|---|
Mortality | 100 (31.7%) | 27 (30.7%) | 40 (24%) | 33 (55%) | 0.001 |
Survival time (month) | 17 (7–110) | 17 (7–90) | 18 (5–110) | 13 (4–88) | 0.036 |
Recurrence | 147 (46.7%) | 38 (43.2%) | 78 (46.7%) | 31 (51.7%) | 0.376 |
Recurrence time (month) | 14 (4–110) | 15 (4–90) | 14 (4–110) | 12 (4–82) | 0.053 |
Recurrence site | Â | Â | Â | Â | 0.804 |
 Intrahepatic | 113 (35.9%) | 30 (34.1%) | 61 (36.5%) | 22 (36.7%) | |
 Extrahepatic | 6 (1.9%) | 1 (1.1%) | 4 (2.4%) | 1 (1.7%) | |
 Both | 28 (8.9%) | 7 (8%) | 13 (7.8%) | 8 (13.3%) | |
Intrahepatic site | Â | Â | Â | Â | 0.059 |
 Liver margin | 7 (2.2%) | 2 (2.3%) | 2 (1.2%) | 3 (5%) | |
 Same liver lobe | 33 (10.5%) | 12 (13.6%) | 16 (9.6%) | 5 (8.3%) | |
 Other liver lobe | 44 (14%) | 9 (10.2%) | 20 (12%) | 15 (25%) | |
 Bilobar | 57 (18.1%) | 14 (15.9%) | 36 (21.6%) | 7 (11.7%) | |
Intrahepatic treatment | Â | Â | Â | Â | 0.047 |
Resection | 2 (0.6%) | 1 (1.1%) | 1 (0.6%) | 0 | |
 TACE | 37 (11.7%) | 6 (6.8%) | 24 (14.4%) | 7 (11.7%) | |
 RFA | 9 (2.9%) | 4 (4.5%) | 4 (2.4%) | 1 (1.7%) | |
 MWA | 10 (3.2%) | 5 (5.7%) | 3 (1.8%) | 2 (3.3%) | |
 Combined therapy | 12 (3.8%) | 7 (7.9%) | 2 (1.2%) | 3 (5%) | |
 Systemic therapy | 1 (0.3%) | 1 (1.1%) | 0 | 0 | |
 Supportive | 70 (22.2%) | 13 (14.8%) | 40 (24%) | 17 (28.3%) | |
Extrahepatic site | Â | Â | Â | Â | 0.492 |
 Lung | 13 (4.1%) | 3 (3.4%) | 5 (3%) | 5 (8.3%) | |
 Bone | 5 (1.6%) | 1 (1.1%) | 4 (2.4%) | 0 | |
 Brain | 1 (0.3%) | 0 | 1 (0.6%) | 0 | |
 Peritoneum | 5 (1.6%) | 2 (2.3%) | 3 (1.8%) | 0 | |
 Adrenal gland | 1 (0.3%) | 0 | 0 | 1 (1.7%) | |
 Abdominal wall | 1 (0.3%) | 1 (1.1%) | 0 | 0 | |
 Lymph nodes | 3 (1%) | 1 (1.1%) | 1 (0.6%) | 1 (1.7%) | |
 Multi-site | 5 (1.6%) | 0 | 3 (1.8%) | 2 (3.3%) |